T1	Person 0 4	Male
T2	Person 8 14	female
*	OR T1 T2
T3	Value 16 24;32 40	18 years or older
T4	Person 28 31	age
R1	Has_value Arg1:T4 Arg2:T3	
T5	Condition 80 108	diabetic macular edema (DME)
T6	Qualifier 57 79	clinically significant
R2	Has_qualifier Arg1:T5 Arg2:T6	
T7	Measurement 114 140	central subfield thickness
T8	Value 141 148	≥ 350µm
T9	Procedure 152 171	spectral domain OCT
R3	AND Arg1:T9 Arg2:T7	
R4	Has_value Arg1:T7 Arg2:T8	
R5	AND Arg1:T5 Arg2:T9	
T10	Measurement 172 207	Best corrected visual acuity (BCVA)
T11	Value 211 243	20/50 to 20/320 ETDRS equivalent
T12	Value 245 269	65 letters to 23 letters
R6	Subsumes Arg1:T11 Arg2:T12	
T13	Qualifier 271 287	in the study eye
R7	Has_qualifier Arg1:T10 Arg2:T13	
R8	Has_value Arg1:T10 Arg2:T11	
T14	Non-representable 289 338	with BCVA decrement primarily attributable to DME
T15	Observation 340 355	Treatment naïve
T16	Negation 363 365	no
T17	Temporal 366 374	previous
T18	Procedure 375 394	anti-VEGF treatment
T19	Qualifier 395 411	in the study eye
R9	Has_qualifier Arg1:T18 Arg2:T19	
R10	Has_temporal Arg1:T18 Arg2:T17	
R11	Has_negation Arg1:T18 Arg2:T16	
T20	Negation 415 417	no
T21	Procedure 418 437	anti-VEGF treatment
T22	Temporal 438 478	in the 45 days prior to study enrollment
T23	Reference_point 462 478	study enrollment
R12	Has_index Arg1:T22 Arg2:T23	
R13	Has_temporal Arg1:T21 Arg2:T22	
R14	Has_negation Arg1:T21 Arg2:T20	
*	OR T21 T18
T24	Scope 363 478	no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment
R15	Subsumes Arg1:T15 Arg2:T24	
T25	Non-query-able 480 509	In the investigator's opinion
T26	Qualifier 533 544	significant
T27	Condition 545 563	intraretinal fluid
T28	Qualifier 564 589	with room for improvement
T29	Non-representable 564 589	with room for improvement
T30	Condition 598 611	macular edema
T31	Condition 616 620	BCVA
T32	Scope 598 620	macular edema and BCVA
R17	Has_qualifier Arg1:T27 Arg2:T26	
R16	Has_scope Arg1:T28 Arg2:T32	
R18	Has_qualifier Arg1:T27 Arg2:T28	
R19	multi Arg1:T28 Arg2:T29	
T33	Measurement 622 649	Intra-Ocular Pressure (IOP)
T34	Value 653 666	under control
T35	Measurement 674 677	IOP
T36	Value 678 685	≤ 25 mm
T37	Qualifier 686 702	in the study eye
R20	Has_value Arg1:T35 Arg2:T36	
R21	Has_qualifier Arg1:T35 Arg2:T37	
R22	Has_value Arg1:T33 Arg2:T34	
T38	Drug 739 757	IOP lowering drops
T39	Negation 721 724	not
R23	Has_negation Arg1:T38 Arg2:T39	
T40	Qualifier 708 717	study eye
R24	Has_qualifier Arg1:T38 Arg2:T40	
T41	Scope 674 702	IOP ≤ 25 mm in the study eye
T42	Scope 622 666	Intra-Ocular Pressure (IOP) is under control
R25	Has_scope Arg1:T42 Arg2:T41	
T43	Post-eligibility 759 807	Willing and able to return for all study visits.
T44	Post-eligibility 808 862	Able to meet the extensive post-op evaluation regimen.
T45	Informed_consent 863 911	Understands and signs the informed consent form.
